Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Xeris Pharmaceuticals , Inc. (NASDAQ:XERS) stock soared to a 52-week high, reaching a price level of $5.54, marking a significant milestone for the company with a market capitalization of $874 million. According to InvestingPro analysis, the stock appears slightly overvalued at current levels. This peak reflects a robust 1-year change, with the stock value surging by an impressive 167.62%. Investors have shown growing confidence in Xeris Pharmaceuticals’ prospects, as the company continues to make strides in its business operations and product development, achieving 23.89% revenue growth and an impressive 81.86% gross profit margin. InvestingPro analysis reveals 8 additional key insights about XERS’s momentum, with analyst price targets ranging from $4 to $8 per share.
In other recent news, Xeris Biopharma Holdings, Inc. reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share of -0.03, compared to the forecasted -0.06. The company also exceeded revenue forecasts, reporting $60.1 million against the anticipated $55.99 million. Additionally, Xeris Biopharma announced the FDA approval of its supplemental new drug application for Gvoke VialDx™, which is intended as a diagnostic aid in radiologic examinations for adults. The company has partnered with American Regent for the commercialization of this product in the United States.
H.C. Wainwright raised the price target on Xeris Pharmaceuticals shares to $8.00 from $6.60, maintaining a Buy rating on the stock. The firm cited strong 2025 guidance and a clear path to cash flow breakeven as reasons for the optimistic outlook. Xeris has projected 2025 revenues between $255-275 million, which was 11% above consensus estimates, indicating a potential growth of approximately 30%. The company’s products, Recorlev and Gvoke, have shown significant growth, contributing to a total revenue of $203.1 million for 2024, marking a 24% growth compared to the previous year.
Xeris Biopharma’s strategic focus on expanding its prescriber base and disciplined expense management has bolstered its competitive position in the endocrinology market. The company also expressed anticipation for mid-year clarity on the development pathway of XP-8121, a potentially transformative once-weekly levothyroxine autoinjector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.